Type 2 Diabetes Prevention and Control Linked to Lower Greenhouse Gas Emissions
Research in the United Kingdom found that preventing type 2 diabetes cut care-related greenhouse gas emissions by about 67%, while well-controlled disease was linked to 21% lower emissions than uncontrolled diabetes.
Effective type 2 diabetes prevention, treatment, and management through early implementation of evidence-based guidelines can not only improve patient outcomes but also reduce health care-related environmental impacts and limit greenhouse gas emissions. By modeling diabetes prevention and improved disease management in the United Kingdom, investigators found that preventing type 2 diabetes could reduce emissions associated with complications by more than half, while optimized disease management alone could lower greenhouse gas emissions by approximately 21%.
Health care accounts for approximately 4% to 5% of global carbon emissions, with pharmaceuticals and medical technologies contributing roughly one-quarter of that burden. The new research, published in Diabetes and Endocrinology, detailed societal benefits related to prompt diagnosis and optimal care for adults with prediabetes or type 2 diabetes.
Investigators utilized a core diabetes model adapted to replace cost inputs with greenhouse gas emissions associated with medical interventions and procedures for the management of type 2 diabetes and its complications. A total of 1000 patients were included in the simulation.
Preventing progression of prediabetes to type 2 diabetes improved undiscounted life years by 6.357 and quality-adjusted life years by 3.747 compared with natural progression. Patients who remained prediabetic exhibited lower diabetes-related complication or event rates compared with patients who progressed naturally to type 2 diabetes.
Total greenhouse gas emissions associated with the care of individuals with prediabetes who did not progress further to type 2 diabetes were approximately 67% less compared with those who naturally progressed to type 2 diabetes. This was driven primarily by the reduced need for managing diabetes-related complications, mainly cardiovascular disease (35.8%), renal disease (97.6%), and eye diseases (73.3) over a lifetime, in addition to avoiding overall type 2 diabetes treatment (88.4%). These reductions are driven by decreased need for resource-intensive care related to complications such as heart failure, kidney failure, and stroke.
For the average patient with well-controlled type 2 diabetes, improved life years and quality-adjusted life years were similarly observed, and these individuals had a lower risk of developing diabetes-related events compared with uncontrolled type 2 diabetes. Caring for patients with well-controlled type 2 diabetes was linked to 21% less greenhouse gas emissions compared with uncontrolled patients. Reductions were mainly due to a lack of management of renal disease (44.9%), cardiovascular disease (20.4%), and eye diseases (24.1%).
If effective therapy for type 2 diabetes was delayed by 2 or 5 years, undiscounted life years were reduced and greenhouse gas emissions over a lifetime associated with well-controlled type 2 diabetes increased, with higher emissions the longer the delay. Even with delays in treatment, greenhouse gas emissions were less for well-controlled type 2 diabetes compared with uncontrolled type 2 diabetes.
The findings reinforce the dual clinical and environmental value of preventive care and adherence support. Preventing progression from prediabetes to type 2 diabetes is associated with approximately 6 additional years of life expectancy and fewer cardiometabolic complications. Pharmacists, as accessible health care professionals, are positioned to promote interventions that simultaneously improve population health outcomes and support sustainability goals within evolving value-based care frameworks.